Acumen Pharmaceuticals, Inc.

ABOS Nasdaq SEC CIK 1576885
Follow Acumen Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$25.4M +4.1% vs same quarter last year
EPS, diluted −$0.35 +20.5% vs same quarter last year
Operating cash flow −$26.7M +12.6% vs same quarter last year
Operating income −$25.8M +2.6% vs same quarter last year
Net income by quarter
−$37.2M
−$28.8M
−$41M
−$26.5M
−$25.1M
−$20.7M
−$32.7M
−$25.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$121.3M
FY24−$102.3M
FY23−$52.4M
FY22−$42.9M
FY21−$100.6M
FY20−$7.3M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$115.6M
FY24−$86.2M
FY23−$43.1M
FY22−$35.3M
FY21−$18M
FY20-
FY19-